Varfarin Kullanımında İntrakraniyal Kanama ve Yönetim İlkeleri
Referanslar
Jonas DE, Bryant Shilliday B, Laundon WR, et al. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2010;30:206–216.
R. Sarode, K. Matevosyan, R. Bhagat, C. Rutherford, C. Madden, and J. E. Beshay. Rapid warfarin reversal: A 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage: J Neurosurg. 2012:116,3:491–497.
S. Schulman, R. J. Beyth, C.Kearon, M.N. Levine. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 2008. 133(6):257S–298S.
Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588–93.
Schols AM, Schreuder FH, van Raak EP, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke. 2014;45:268–70.
Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology.
2007;68:116–21.
Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78(1):54–62.
Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018 May 15;71 (19): 2162-2175.
Tsivgoulis G, Wilson D, Katsanos AH, et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol. 2018;84(5):694-704.
Gerner ST, Kuramatsu JB, Sembill JA, et al; RETRACE II (German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage II) Investigators. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018 Jan;83(1):186-196.
Le Roux P, Pollack CV, Milan M, Schaefer A. Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage J Neurosurg (Suppl) 121:1–20, 2014.
Bechtel BF, Nunez TC, Lyon JA, et al. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med. 2011;4(1):40.
Flaherty ML, Adeoye O, Sekar P, et al. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke. 2009;40:1738–1742.
Freeman WD, Aguilar MI. Management of warfarin-related intracerebral hemorrhage. Expert Rev Neurother. 2008;8:271–90.
Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39:2993–2996.
Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43:1812–1817.
US Food and Drug Administration. FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. April 29, 2013. Available at: www.fda.gov/NewsEvents/Newsroom/Pressannouncements/ucm350026.htm.
Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017;44(1):118-129.
Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.
Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–36.
Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71(14):1084–9.
Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 2014;71:158–164.
Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol. 2012;259:212–224.
Kuwashiro T, Yasaka M, Itabashi R, et al. Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage. Cerebrovasc Dis. 2011;31:170–6.
Kuramatsu JB, Sembill JA, Huttner HB. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. Crit Care. 2019;23(1):206. Published 2019 Jun 6. doi:10.1186/s13054-019-2492-8
Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.
Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016;15(6):566-73.
Neal M, Crowther M, Douketis J, et al. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice. Thromb Res 2008;122:864–866.
Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin –fourth edition. Br J Haematol 2011;154:311–24.
Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S
Hörer T, DuBose JJ, Rasmussen TE, White JM. Editors. Endovascular Resuscitation and Trauma Management; Bleeding and Haemodynamic Control. Springer Nature Switzerland AG 2020
Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016;116(5):879-890.
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067.
Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43.
Morgenstern LB, Hemphill JC III, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2010;41:2108–29.
Pagano MB, Foroutan F, Goel R, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion. 2022;62(8):1652-1661. doi: 10.1111/trf.17010.
Vitt JR, Do LV, Shah NH, Fong G, Nguyen NY, Kim AS. Before-After Study of an Electronic Order Set for Reversal of Vitamin K Antagonist-Associated Intracerebral Hemorrhage. Neurohospitalist. 2018;8(1):18–23. doi:10.1177/1941874417714706
Di Fusco SA, Lucà F, Benvenuto M, et al. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents. Int J Cardiol. 2018;268:75-79.
Eby CS. Bleeding and Vitamin K Deficiency. In: Teruya J. Management of Bleeding Patients. Springer International Publishing Switzerland 2016.
Sprigg N, Flaherty K, Appleton JP, et al. TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018 May 26;391(10135):2107-2115.
Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev 2015;7:Cd010555.
Woo CH, Patel N, Conell C, et al. Rapid Warfarin Reversal in the Setting of Intracranial Hemorrhage: A Comparison of Plasma, Recombinant Activated Factor VII, and Prothrombin Complex Concentrate. World Neurosurg. 2014;81(1):110-5.
Dager WE. Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects. Ann Pharmacother 2011;45:1016–20.
Joseph R, Burner J, Yates S, Strickland A, Tharpe W, Sarode R. Thromboembolic outcomes after use of a four-factor Prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion (Paris). 2015;56:799–807.
Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.
Sadeghi N, Kahn D, Cunanan J, et al. Compositional differences in commercially available prothrombin complex concentrates. Blood 2012;120.
Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 2012;130:833–40.
Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis. Neurocrit Care. 2017;26(1):64-69.
Mohammadi K, Yaribash S, Sani MA, Talasaz AH. Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2022;36(3):533-546. doi: 10.1007/s10557-021-07192-0.
R. Sarode, K. Matevosyan, R. Bhagat, C. Rutherford, C. Madden, and J. E. Beshay. Rapid warfarin reversal: A 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage: J Neurosurg. 2012:116,3:491–497.
S. Schulman, R. J. Beyth, C.Kearon, M.N. Levine. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition), Chest, 2008. 133(6):257S–298S.
Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588–93.
Schols AM, Schreuder FH, van Raak EP, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke. 2014;45:268–70.
Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology.
2007;68:116–21.
Parry-Jones AR, Di Napoli M, Goldstein JN, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol. 2015;78(1):54–62.
Qamar A, Vaduganathan M, Greenberger NJ, Giugliano RP. Oral anticoagulation in patients with liver disease. J Am Coll Cardiol. 2018 May 15;71 (19): 2162-2175.
Tsivgoulis G, Wilson D, Katsanos AH, et al. Neuroimaging and clinical outcomes of oral anticoagulant-associated intracerebral hemorrhage. Ann Neurol. 2018;84(5):694-704.
Gerner ST, Kuramatsu JB, Sembill JA, et al; RETRACE II (German-Wide Multicenter Analysis of Oral Anticoagulation-Associated Intracerebral Hemorrhage II) Investigators. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol. 2018 Jan;83(1):186-196.
Le Roux P, Pollack CV, Milan M, Schaefer A. Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage J Neurosurg (Suppl) 121:1–20, 2014.
Bechtel BF, Nunez TC, Lyon JA, et al. Treatments for reversing warfarin anticoagulation in patients with acute intracranial hemorrhage: a structured literature review. Int J Emerg Med. 2011;4(1):40.
Flaherty ML, Adeoye O, Sekar P, et al. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage. Stroke. 2009;40:1738–1742.
Freeman WD, Aguilar MI. Management of warfarin-related intracerebral hemorrhage. Expert Rev Neurother. 2008;8:271–90.
Cucchiara B, Messe S, Sansing L, et al. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke. 2008;39:2993–2996.
Dowlatshahi D, Butcher KS, Asdaghi N, et al. Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke. 2012;43:1812–1817.
US Food and Drug Administration. FDA approves Kcentra for the urgent reversal of anticoagulation in adults with major bleeding. April 29, 2013. Available at: www.fda.gov/NewsEvents/Newsroom/Pressannouncements/ucm350026.htm.
Brekelmans MPA, Ginkel KV, Daams JG, Hutten BA, Middeldorp S, Coppens M. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis. J Thromb Thrombolysis. 2017;44(1):118-129.
Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology. 2004;63:1059–64.
Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–36.
Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, et al. Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 71(14):1084–9.
Brouwers HB, Chang Y, Falcone GJ, et al. Predicting hematoma expansion after primary intracerebral hemorrhage. JAMA Neurol 2014;71:158–164.
Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol. 2012;259:212–224.
Kuwashiro T, Yasaka M, Itabashi R, et al. Effect of prothrombin complex concentrate on hematoma enlargement and clinical outcome in patients with anticoagulant-associated intracerebral hemorrhage. Cerebrovasc Dis. 2011;31:170–6.
Kuramatsu JB, Sembill JA, Huttner HB. Reversal of oral anticoagulation in patients with acute intracerebral hemorrhage. Crit Care. 2019;23(1):206. Published 2019 Jun 6. doi:10.1186/s13054-019-2492-8
Davis SM, Broderick J, Hennerici M, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175–81.
Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol 2016;15(6):566-73.
Neal M, Crowther M, Douketis J, et al. Reversal of vitamin K antagonist-associated coagulopathy: a survey of current practice. Thromb Res 2008;122:864–866.
Keeling D, Baglin T, Tait C, et al. Guidelines on oral anticoagulation with warfarin –fourth edition. Br J Haematol 2011;154:311–24.
Holbrook A, Schulman S, Witt DM et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S
Hörer T, DuBose JJ, Rasmussen TE, White JM. Editors. Endovascular Resuscitation and Trauma Management; Bleeding and Haemodynamic Control. Springer Nature Switzerland AG 2020
Chai-Adisaksopha C, Hillis C, Siegal DM, et al. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost 2016;116(5):879-890.
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017 Dec 19;70(24):3042-3067.
Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–43.
Morgenstern LB, Hemphill JC III, Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2010;41:2108–29.
Pagano MB, Foroutan F, Goel R, et al. Vitamin K antagonist reversal strategies: Systematic review and network meta-analysis from the AABB. Transfusion. 2022;62(8):1652-1661. doi: 10.1111/trf.17010.
Vitt JR, Do LV, Shah NH, Fong G, Nguyen NY, Kim AS. Before-After Study of an Electronic Order Set for Reversal of Vitamin K Antagonist-Associated Intracerebral Hemorrhage. Neurohospitalist. 2018;8(1):18–23. doi:10.1177/1941874417714706
Di Fusco SA, Lucà F, Benvenuto M, et al. Major bleeding with old and novel oral anticoagulants: How to manage it. Focus on reversal agents. Int J Cardiol. 2018;268:75-79.
Eby CS. Bleeding and Vitamin K Deficiency. In: Teruya J. Management of Bleeding Patients. Springer International Publishing Switzerland 2016.
Sprigg N, Flaherty K, Appleton JP, et al. TICH-2 Investigators. Tranexamic acid for hyperacute primary IntraCerebral Haemorrhage (TICH-2): an international randomised, placebo-controlled, phase 3 superiority trial. Lancet. 2018 May 26;391(10135):2107-2115.
Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev 2015;7:Cd010555.
Woo CH, Patel N, Conell C, et al. Rapid Warfarin Reversal in the Setting of Intracranial Hemorrhage: A Comparison of Plasma, Recombinant Activated Factor VII, and Prothrombin Complex Concentrate. World Neurosurg. 2014;81(1):110-5.
Dager WE. Using prothrombin complex concentrates to rapidly reverse oral anticoagulant effects. Ann Pharmacother 2011;45:1016–20.
Joseph R, Burner J, Yates S, Strickland A, Tharpe W, Sarode R. Thromboembolic outcomes after use of a four-factor Prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion (Paris). 2015;56:799–807.
Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: Prothrombin complex concentrates–evaluation of safety and thrombogenicity. Crit Care. 2011;15:201.
Sadeghi N, Kahn D, Cunanan J, et al. Compositional differences in commercially available prothrombin complex concentrates. Blood 2012;120.
Voils SA, Baird B. Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter? Thromb Res 2012;130:833–40.
Abdoellakhan RA, Miah IP, Khorsand N, Meijer K, Jellema K. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis. Neurocrit Care. 2017;26(1):64-69.
Mohammadi K, Yaribash S, Sani MA, Talasaz AH. Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther. 2022;36(3):533-546. doi: 10.1007/s10557-021-07192-0.
Sayfalar
83-94
Gelecek
23 Ocak 2023
Telif Hakkı (c) 2023 Akademisyen Kitap Portalı
Lisans
LisansNasıl Atıf Yapılır
1.
Ergün Süzer N. Varfarin Kullanımında İntrakraniyal Kanama ve Yönetim İlkeleri. Içinde: Kekeç Z, editör. Güncel Acil Tıp Çalışmaları III [Internet]. Türkiye: Akademisyen Yayınevi Kitap DOI Portalı; 2023 [a.yer 16 Temmuz 2026]. ss. 83-94. Erişim adresi: https://omp35.books.akademisyen.net/index.php/akya/catalog/book/2461/chapter/14505
